Urinary tract infection

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

Retrieved on: 
Thursday, February 24, 2022

AUSTIN, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that results from its recently completed in vitro neutralization and viral replication assays indicate that the Company’s inhaled niclosamide product candidate completely inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2.

Key Points: 
  • Compared to data from previously published studies, the results demonstrate that inhaled niclosamide appears to be the most potent inhibitor of SARS-CoV-2 replication, including the Omicron variant.
  • More specifically, nirmatrelvir and molnupiravir each showed complete inhibition of the Omicron variant at 2.5M.1 In the studies announced today by TFF Pharmaceuticals, inhaled niclosamide demonstrated complete inhibition of Omicron at only 1M.
  • In a Phase 1 study, TFF Pharmaceuticals has already demonstrated that a 6 mg BID dosing of inhaled niclosamide is well tolerated.
  • The data demonstrating that niclosamide inhibits viral replication of the Omicron variant is proof of concept for the activity of the drug against SARS-CoV-2, said Dr. Michael Saag, Professor of Medicine at UAB School of Medicine and Member of the TFF Pharmaceuticals Scientific Advisory Board.Niclosamides mechanism of action, which inhibits human pathways involved in viral replication, restricts development of mutations in the viral genome.

FDA Approves Treatment for Wider Range of Patients with Heart Failure

Retrieved on: 
Thursday, February 24, 2022

"Today's approval will provide a treatment option for a wider range of patients with heart failure," said Norman Stockbridge, M.D., Ph.D., Director of the Division of Cardiology and Nephrology in the FDA's Center for Drug Evaluation and Research.

Key Points: 
  • "Today's approval will provide a treatment option for a wider range of patients with heart failure," said Norman Stockbridge, M.D., Ph.D., Director of the Division of Cardiology and Nephrology in the FDA's Center for Drug Evaluation and Research.
  • "While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure.
  • Despite therapies in multiple drug classes, mortality remains high and treatment options for a broader range of patients are needed.
  • The side effects in clinical studies with Jardiance for patients with heart failure were generally consistent with side effects for patients with diabetes.

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Talis Biomedical Corporation

Retrieved on: 
Thursday, February 24, 2022

Kessler Topaz is one of the worlds foremost advocates in protecting the public against corporate fraud and other wrongdoing.

Key Points: 
  • Kessler Topaz is one of the worlds foremost advocates in protecting the public against corporate fraud and other wrongdoing.
  • Kessler Topaz Meltzer & Check, LLP encourages Talis investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

Pomerantz Law Firm Announces the Filing of a Class Action Against Talis Biomedical Corporation and Certain Officers and Directors – TLIS

Retrieved on: 
Tuesday, February 22, 2022

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Talis Biomedical Corporation (Talis or the Company) (NASDAQ: TLIS) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Talis Biomedical Corporation (Talis or the Company) (NASDAQ: TLIS) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Talis Biomedical Corporation – TLIS

Retrieved on: 
Wednesday, February 16, 2022

RADNOR, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Talis Biomedical Corporation (Talis) ( NASDAQ: TLIS ).

Key Points: 
  • RADNOR, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Talis Biomedical Corporation (Talis) ( NASDAQ: TLIS ).
  • Kessler Topaz Meltzer & Check, LLP encourages Talis investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital

Retrieved on: 
Wednesday, February 16, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero’s potentiator platform and is in development to treat serious multi-drug resistant (MDR) gram-negative infections in the hospital setting.

Key Points: 
  • SPR206 was derived from Speros potentiator platform and is in development to treat serious multi-drug resistant (MDR) gram-negative infections in the hospital setting.
  • The Phase 1 BAL study evaluated the safety and pharmacokinetics (PK) of SPR206 when administered at 100 mg, three times daily.
  • Together with our prior Phase 1 and pre-clinical data, we look forward to engaging with regulators as we plan the continued development of SPR206.
  • The Phase 1 BAL clinical trial was an open-label study designed to enroll 30 healthy volunteers into five cohorts.

News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19

Retrieved on: 
Tuesday, February 15, 2022

An article published by BioSpace titled How Pharma and Academia are Tackling the Opioid Epidemic includes insight from Anthony Mack, CEO of Virpax, about the opioid crisis and the companys development of non-addictive pain management solutions.

Key Points: 
  • An article published by BioSpace titled How Pharma and Academia are Tackling the Opioid Epidemic includes insight from Anthony Mack, CEO of Virpax, about the opioid crisis and the companys development of non-addictive pain management solutions.
  • Along with AnQlar, Epoladerm, and Probudur, Mack discusses Envelta, Virpaxs investigational endogenous enkephalin intranasal spray for acute and chronic pain, including pain associated with cancer.
  • Dr. Sheila Mathias, Chief Scientific Officer of Virpax, was interviewed on PharmaVoices Woman of the Week (WOW) podcast discussing her leadership skills and the Virpax portfolio of products in development.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Retrieved on: 
Monday, February 14, 2022

A Breakthrough Therapy Designation is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition.

Key Points: 
  • A Breakthrough Therapy Designation is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition.
  • The designation provides an option to work more closely with FDA for the development and review of MVA-BN RSV.
  • MVA-BN RSV, Bavarian Nordic's vaccine candidate for the prevention of RSV, is being developed for use in elderly individuals.
  • The MVA-BN RSV vaccine demonstrated a vaccine efficacy of up to 79% in preventing symptomatic RSV infections3.

Chronic Obstructive Pulmonary Disease Drug Pipeline Market Report 2022: Comprehensive Insights About 70+ Companies and 70+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 10, 2022

The report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape.

Key Points: 
  • The report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape.
  • A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines.
  • The assessment part of the report embraces, in depth Chronic Obstructive Pulmonary Disease commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D.

Sauro-Throat! First evidence of dinosaur respiratory infection

Retrieved on: 
Thursday, February 10, 2022

POMONA, Calif., Feb. 10, 2022 /PRNewswire-PRWeb/ --The fossilized remains of an immature diplodocid a large, long- necked herbivorous sauropod dinosaur, like "Brontosaurus" may provide the first evidence of a unique respiratory infection in a dinosaur, according to a study published in Scientific Reports.

Key Points: 
  • POMONA, Calif., Feb. 10, 2022 /PRNewswire-PRWeb/ --The fossilized remains of an immature diplodocid a large, long- necked herbivorous sauropod dinosaur, like "Brontosaurus" may provide the first evidence of a unique respiratory infection in a dinosaur, according to a study published in Scientific Reports.
  • These air sacs would have ultimately connected to "Dolly's" lungs and formed part of the dinosaur's complex respiratory system.
  • The authors speculate that this respiratory infection could have been caused by a fungal infection similar to aspergillosis, a common respiratory illness that affects birds and reptiles today and can lead to bone infections.
  • In addition to documenting the first occurrence of such a respiratory infection in a dinosaur, this fossilized infection also has important anatomical implications for the respiratory system of sauropod dinosaurs.